[18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives

Salim Kanoun (1) , Cédric Rossi (2, 3) , Olivier Casasnovas (3, 4, 5)

1 Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon)
2 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
3 Service d'Hématologie Clinique (CHU de Dijon)
4 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
5 UBFC - Université Bourgogne Franche-Comté [COMUE]

Functional imaging using 18-fluorodeoxyglycose ([18F]FDG) positron emission tomography combined with computed tomography (PET/CT) has become a major imaging modality in Hodgkin lymphoma. This imaging modality allows for a significant improvement in staging, increased sensitivity, which involves differentiating residual tumors from fibrosis during assessment, and highly impacts treatment decisions into new PET-driven strategies. This review presents the main scientific data concerning the current applications of [18F]FDG-PET/CT in Hodgkin lymphoma at baseline, interim, and the end of treatment evaluation along with the main PET-driven trials for therapeutic decisions. The emergence of total metabolic tumor volume as a new functional prognostic factor will also be discussed.

Mots clés: Hodgkin Lymphoma; PET/CT; [18F]FDG; interim PET; staging; total metabolic tumor volume; treatment response

Domaines: Cancer

Salim Kanoun, Cédric Rossi, Olivier Casasnovas. [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers, 2018, 10 (5), pp.145. ⟨10.3390/cancers10050145⟩. ⟨hal-01922795⟩